On Sunday, April 20th 2025, starting 8:30am GMT, there will be maintenance work that will involve the website being unavailable during parts of the day. We apologize for any inconvenience this may cause and appreciate your understanding.
We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Many antibiotics inhibit the ribosome
- Intelligent engine builds perpetual pipeline (1)
- Crystallography shows 50s is a target-of-targets
- From new X-ray crystals to new leads
- AnalogTM
- LINKER essentials: tethering two binding features
- BOMB essentials: grow
- BOMB essentials: grow, search
- BOMB essentials: score, refine
- MUSIC essentials: core-swapping
- QikProp - calculating drug-like properties
- Structures + AnalogTM: balanced compounds
- Case study: enhanced oxazolidinones
- Structural foundations
- Path to enhanced oxazolidinones
- Py contributions represent key interactions
- Probing selectivity of sparsomycin
- Seeking a new lead
- The results (1)
- Difference density map showing rib-X prototype
- Modeling - a perfect match
- The results (2)
- A minimal scaffold for lead optimization
- Minimal scaffold binds effectively in A-site
- Activity against H. influenzae
- H. influenzae activity with time evolution
- H. flu model delivers differentiable oxazolidinones
- Moderate in vivo activity measured
- Predictive model for rat oral bioavailability
- First pool of drug candidates
- Structures + predictive models = time-saving filters
- Intelligent engine builds perpetual pipeline (2)
- Acknowledgments
Topics Covered
- Many antibiotics inhibit the ribosome
- Intelligent engine builds perpetual pipeline
- Crystallography shows 50S is a target-of-targets
- From new X-ray crystals to new leads
- Analog(Trade Mark)
- LINKER essentials: tethering two binding features
- BOMB essentials
- MUSIC essentials: core-swapping
- QikProp: calculating drug-like properties
- Structures + Analog(Trade Mark): balanced compounds
- Case study: enhanced oxazolidinones
- Structural foundations
- Path to enhanced oxazolidinones
- Pi contributions represent key interactions
- Probing selectivity of sparsomycin
- Seeking a new lead
- Difference density map showing rib-X prototype
- Perfect match
- A minimal scaffold for lead optimization
- Minimal scaffold binds effectively in A-site
- Activity against H. influenzae
- H. influenzae activity with time evolution
- H. flu model delivers differentiable oxazolidinones
- Moderate in vivo activity measured
- Predictive model for rat oral bioavailability
- First pool of drug candidates
- Structures + predictive models = time-saving filters
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Duffy, E. (2008, May 15). Structure-based drug design targeting infectious disease [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 15, 2025, from https://doi.org/10.69645/ISPB8442.Export Citation (RIS)
Publication History
- Published on May 15, 2008
Financial Disclosures
- Dr. Erin Duffy has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.